Detalhe da pesquisa
1.
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Br J Cancer
; 130(3): 425-433, 2024 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38097739
2.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37052965
3.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36965291
4.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37355448
5.
How to sequence treatment in relapsed ovarian cancer.
Future Oncol
; 17(3s): 1-8, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-33355013
6.
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Int J Gynecol Cancer
; 31(1): 110-113, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32796087
7.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer
; 31(7): 1031-1036, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33990353
8.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33931498
9.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34462317
10.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol
; 156(1): 38-44, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31699415
11.
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Support Care Cancer
; 28(5): 2435-2442, 2020 May.
Artigo
Inglês
| MEDLINE | ID: mdl-32048043
12.
Treatment of recurrent epithelial ovarian cancer.
Cancer
; 125 Suppl 24: 4609-4615, 2019 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31967680
13.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol
; 154(1): 83-88, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31029508
14.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Gynecol Oncol
; 153(3): 535-540, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30979589
15.
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Support Care Cancer
; 25(6): 1743-1748, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28101677
16.
Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer.
Oncology
; 90(1): 29-35, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26473609
17.
Ovarian cancer standard of care: are there real alternatives?
Chin J Cancer
; 34(1): 17-27, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25556615
18.
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Oncology
; 86(5-6): 351-8, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24942520
19.
Safety of PARP inhibitors as maintenance therapy in ovarian cancer.
Expert Opin Drug Saf
; 22(10): 897-908, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37668154
20.
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention.
Biomolecules
; 13(4)2023 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37189400